These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22178465)

  • 1. OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials.
    Manno RL; Bingham CO; Paternotte S; Gossec L; Halhol H; Giacovelli G; Rovati L; Mazzuca SA; Clegg DO; Shi H; Tajana Messi E; Lanzarotti A; Dougados M
    Osteoarthritis Cartilage; 2012 Feb; 20(2):93-101. PubMed ID: 22178465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OARSI/OMERACT criteria of being considered a candidate for total joint replacement in knee/hip osteoarthritis as an endpoint in clinical trials evaluating potential disease modifying osteoarthritic drugs.
    Dougados M; Hawker G; Lohmander S; Davis AM; Dieppe P; Maillefert JF; Gossec L
    J Rheumatol; 2009 Sep; 36(9):2097-9. PubMed ID: 19738220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group.
    Gossec L; Paternotte S; Bingham CO; Clegg DO; Coste P; Conaghan PG; Davis AM; Giacovelli G; Gunther KP; Hawker G; Hochberg MC; Jordan JM; Katz JN; Kloppenburg M; Lanzarotti A; Lim K; Lohmander LS; Mahomed NN; Maillefert JF; Manno RL; March LM; Mazzuca SA; Pavelka K; Punzi L; Roos EM; Rovati LC; Shi H; Singh JA; Suarez-Almazor ME; Tajana-Messi E; Dougados M;
    J Rheumatol; 2011 Aug; 38(8):1765-9. PubMed ID: 21807799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.
    Yazici Y; McAlindon TE; Fleischmann R; Gibofsky A; Lane NE; Kivitz AJ; Skrepnik N; Armas E; Swearingen CJ; DiFrancesco A; Tambiah JRS; Hood J; Hochberg MC
    Osteoarthritis Cartilage; 2017 Oct; 25(10):1598-1606. PubMed ID: 28711582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis.
    Gossec L; Hawker G; Davis AM; Maillefert JF; Lohmander LS; Altman R; Cibere J; Conaghan PG; Hochberg MC; Jordan JM; Katz JN; March L; Mahomed N; Pavelka K; Roos EM; Suarez-Almazor ME; Zanoli G; Dougados M
    J Rheumatol; 2007 Jun; 34(6):1432-5. PubMed ID: 17552070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.
    Abadie E; Ethgen D; Avouac B; Bouvenot G; Branco J; Bruyere O; Calvo G; Devogelaer JP; Dreiser RL; Herrero-Beaumont G; Kahan A; Kreutz G; Laslop A; Lemmel EM; Nuki G; Van De Putte L; Vanhaelst L; Reginster JY;
    Osteoarthritis Cartilage; 2004 Apr; 12(4):263-8. PubMed ID: 15023377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size calculations for detecting disease-modifying osteoarthritis drug effects on the incidence of end-stage knee osteoarthritis in clinical trials: Data from the Osteoarthritis Initiative.
    Flechsenhar K; Ried JS; Driban JB; Price LL; McAlindon T
    Semin Arthritis Rheum; 2019 Aug; 49(1):3-8. PubMed ID: 30611544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs.
    Verbruggen G; Goemaere S; Veys EM
    Clin Rheumatol; 2002 Jun; 21(3):231-43. PubMed ID: 12111630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is knee radiography useful for studying the efficacy of a disease-modifying osteoarthritis drug in humans?
    Mazzuca SA; Brandt KD
    Rheum Dis Clin North Am; 2003 Nov; 29(4):819-30. PubMed ID: 14603585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Inverse OARSI-OMERACT Criteria Is a Valid Indicator of the Clinical Worsening of Knee Osteoarthritis: Data From the Osteoarthritis Initiative.
    Driban JB; Harkey MS; Price LL; Lo GH; McAlindon TE
    J Rheumatol; 2021 Mar; 48(3):442-446. PubMed ID: 32541081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations when designing a disease-modifying osteoarthritis drug (DMOAD) trial using radiography.
    Hellio Le Graverand MP; Clemmer RS; Brunell RM; Hayes CW; Miller CG; Vignon E
    Semin Arthritis Rheum; 2013 Aug; 43(1):1-8. PubMed ID: 23290692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database.
    Dworkin RH; Peirce-Sandner S; Turk DC; McDermott MP; Gibofsky A; Simon LS; Farrar JT; Katz NP
    Osteoarthritis Cartilage; 2011 May; 19(5):483-92. PubMed ID: 21396467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-Hoc analysis of a head-to-head hyaluronic acid comparison in knee osteoarthritis using the 2004 OMERACT-OARSI responder criteria.
    Onel E; Kolsun K; Kauffman JI
    Clin Drug Investig; 2008; 28(1):37-45. PubMed ID: 18081359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plain radiography or magnetic resonance imaging (MRI): Which is better in assessing outcome in clinical trials of disease-modifying osteoarthritis drugs? Summary of a debate held at the World Congress of Osteoarthritis 2014.
    Eckstein F; Le Graverand MP
    Semin Arthritis Rheum; 2015 Dec; 45(3):251-6. PubMed ID: 26142321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of obesity, structural severity and their combination on the efficacy of viscosupplementation in patients with knee osteoarthritis.
    Conrozier T; Eymard F; Chouk M; Chevalier X
    BMC Musculoskelet Disord; 2019 Aug; 20(1):376. PubMed ID: 31421686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.
    Pham T; van der Heijde D; Altman RD; Anderson JJ; Bellamy N; Hochberg M; Simon L; Strand V; Woodworth T; Dougados M
    Osteoarthritis Cartilage; 2004 May; 12(5):389-99. PubMed ID: 15094138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Roman-Blas JA; Castañeda S; Sánchez-Pernaute O; Largo R; Herrero-Beaumont G;
    Arthritis Rheumatol; 2017 Jan; 69(1):77-85. PubMed ID: 27477804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OARSI-OMERACT definition of relevant radiological progression in hip/knee osteoarthritis.
    Ornetti P; Brandt K; Hellio-Le Graverand MP; Hochberg M; Hunter DJ; Kloppenburg M; Lane N; Maillefert JF; Mazzuca SA; Spector T; Utard-Wlerick G; Vignon E; Dougados M
    Osteoarthritis Cartilage; 2009 Jul; 17(7):856-63. PubMed ID: 19230857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Triamcinolone Hexacetonide versus Methylprednisolone Acetate Intraarticular Injections in Knee Osteoarthritis: A Randomized, Double-blinded, 24-week Study.
    Lomonte AB; de Morais MG; de Carvalho LO; Zerbini CA
    J Rheumatol; 2015 Sep; 42(9):1677-84. PubMed ID: 26136485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chondroitin for osteoarthritis.
    Singh JA; Noorbaloochi S; MacDonald R; Maxwell LJ
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD005614. PubMed ID: 25629804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.